Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| International Society for Gastrointestinal Hereditary Tumours |
RCV000075475 | SCV000106472 | pathogenic | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Multifactorial likelihood analysis posterior probability >0.99 |
| Ambry Genetics | RCV002415421 | SCV002717719 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-06-17 | criteria provided, single submitter | clinical testing | The p.G67W pathogenic mutation (also known as c.199G>T), located in coding exon 2 of the MLH1 gene, results from a G to T substitution at nucleotide position 199. The glycine at codon 67 is replaced by tryptophan, an amino acid with highly dissimilar properties. This mutation was identified as homozygous in three siblings with CMMRD from a French family meeting Amsterdam criteria; microsatellite instability was confirmed in normal buccal cells from one of the affected siblings (Wang Q et al. Hum. Genet.;105:79-85; Wang Q et al. Cancer Res. 1999 Jan;59:294-7; Bertholon J et al. Fam. Cancer 2006;5:29-34; Wimmer K et al. Hum. Genet. 2008 Sep;124:105-22; Lavoine N et al. J. Med. Genet. 2015 Nov;52:770-8). The "G67W, 199G>T" alteration showed reduced MMR activity in vitro (7.3%), which was supported by yeast based assays showing no dominant mutator effect (Takahashi M et al. Cancer Res. 2007 May;67:4595-604). This alteration has been classified as pathogenic using the following lines of evidence: in silico prediction models, segregation with disease, clinical phenotype including tumor characteristics, mutation co-occurrence, and functional studies (Thompson BA et al. Nat. Genet. 2014 Feb;46:107-15; available at [www.insight-group.org/variants/classifications/]). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by Bayesdel in silico analysis. In addition, this alteration is predicted to be deleterious by MAPP-MMR in silico analyses (Chao EC et al. Hum. Mutat. 2008 Jun;29:852-60). Of note, this mutation is also designated as "codon 67, GGG>TGG, Gly>Trp" and Gly67Trp in published literature. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Myriad Genetics, |
RCV000018618 | SCV004187602 | pathogenic | Colorectal cancer, hereditary nonpolyposis, type 2 | 2023-07-12 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. Functional studies indicate this variant impacts protein function [PMID: 17510385]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 10480359, 9927034, 21642682]. This variant is expected to disrupt protein structure [Myriad internal data]. |
| OMIM | RCV000018618 | SCV000038901 | pathogenic | Colorectal cancer, hereditary nonpolyposis, type 2 | 1999-01-15 | no assertion criteria provided | literature only | |
| OMIM | RCV001267885 | SCV001446364 | pathogenic | Mismatch repair cancer syndrome 1 | 1999-01-15 | no assertion criteria provided | literature only |